Community Corner
Rye Brook Pathology Services Provider Announces Collaboration with Agendia to Help Breast Cancer Patients
The collaboration between the two companies will benefit both physicians who treat breast cancer patients and the women who have the disease.
Neil Barth, M.D., Agendia’s Chief Medical Officer explained why. “A large part of CBLPath’s focus is on breast cancer. Agendia’s MammaPrint test is a sophisticated assay for breast cancer recurrence risk. Through our BluePrint assay, we also provide a widely available test for molecular subtyping of breast cancer. By working more closely together, Agendia and CBLPath will move the treatment of breast cancer toward better outcomes and fewer unnecessary side-effects.”
Carlos D. Urmacher, M.D., FCAP, FASCP, Co-Chief Executive Officer and Chief Medical Officer of CBLPath said,“CBLPath’s expertise in breast pathology coupled with Agendia’s innovative tests will provide definitive information for breast cancer patients and their physicians when evaluating treatment options. Given the prominence of CBLPath and Agendia in providing sophisticated laboratory services in this field, I look forward to a powerfully synergistic relationship between the two companies.”
The American Cancer Society estimates there will be more than 40,000 deaths due to breast cancer for both males and females for the year 2014. Of that number, 40,000 deaths will be females and 430 males. More than 15,000 of those estimated deaths will be New York females with breast cancer. Early detection is key in the prevention of spreading and treatment of the disease, according to the American Cancer Society. Click here to read the full report.
Find out what's happening in Pleasantville-Briarcliff Manorwith free, real-time updates from Patch.
To read the full article on Digital Journal, click here.
About CBLPath
Find out what's happening in Pleasantville-Briarcliff Manorwith free, real-time updates from Patch.
CBLPath, a Sonic Healthcare USA laboratory, is a leading pathology services provider, combining anatomic pathology with advanced molecular diagnostics, esoteric testing, and digital pathology. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists dedicated to utilizing and integrating comprehensive diagnostic, prognostic, and theranostic testing designed to deliver personalized medicine and to provide our subspecialty physician clients timely, accurate results enabling the most effective patient care. For more about the company, please visit CBLPath.com.
About Agendia
Agendia is a leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's tests were developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology. MammaPrint is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient's individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with other companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.
